People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Areteia Therapeutics, Inc. | — | Biotechnology | Series D+ | $360.0M | $7.8B | 2022 |
Jorge E. Bartolome at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jorge E. Bartolome on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen E. Butts | 1 | 4 |
| Michael E. Bozik | 1 | 3 |
| Adam Koppel | 1 | 3 |
| Paul Berns | 1 | 3 |
| Ian Read | 1 | 2 |
| Robin E. Walker | 1 | 1 |
| Whit E. Bernard | 1 | 1 |
| Christopher E. Courts | 1 | 1 |
| Elyse E. Stock | 1 | 1 |
| Chris E. Visioli | 1 | 1 |
| Benjamin Gomez | 1 | 1 |
| Daniel E. Becker | 1 | 1 |
| Christopher Todd Cox | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.